Merck & Co. Joins Competitive BTK Research Space With $2.7bn ArQule Buy
Executive Summary
ArQule's lead candidate, ARQ 531, is a novel BTK inhibitor in Phase II development that could work in patients with B-cell malignancies resistant to existing BTK inhibitors like Imbruvica.
You may also be interested in...
Gilead/Kite Gain Second CAR-T Approval With Tecartus, Price On Par With Their First
As the first company with two approved chimeric antigen receptor T-cell therapies, Gilead’s Kite subsidiary has set a precedent by keeping the pricing the same as its first approved CAR-T, Yescarta.
Novartis’s Capmatinib Shows High Response Rates In NSCLC
The MET inhibitor already pending US FDA approval had good results in patients with brain metastases. Spectrum’s TKI inhibitor poziotinib continues to be studied after Cohort 1 failure.
Basilea Stresses Derazantinib's FGFR Kinase Differentiation
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Need a specific report? 1000+ reports available
Buy Reports